Rep. Josh Gottheimer Sells ICU Medical, Inc. (NASDAQ:ICUI) Shares

Representative Josh Gottheimer (D-New Jersey) recently sold shares of ICU Medical, Inc. (NASDAQ:ICUI). In a filing disclosed on November 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in ICU Medical stock on October 31st. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.

Representative Josh Gottheimer also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Texas Capital Bancshares (NASDAQ:TCBI) on 10/31/2024.
• Sold $1,001 – $15,000 in shares of ITT (NYSE:ITT) on 10/31/2024.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 10/31/2024.
• Sold $1,001 – $15,000 in shares of AppFolio (NASDAQ:APPF) on 10/31/2024.
• Purchased $1,001 – $15,000 in shares of Gates Industrial (NYSE:GTES) on 10/31/2024.
• Purchased $1,001 – $15,000 in shares of Techtronic Industries (OTCMKTS:TTNDY) on 10/29/2024.
• Purchased $1,001 – $15,000 in shares of Techtronic Industries (OTCMKTS:TTNDY) on 10/28/2024.
• Purchased $1,001 – $15,000 in shares of Disco (OTCMKTS:DSCSY) on 10/28/2024.
• Purchased $1,001 – $15,000 in shares of Enerpac Tool Group (NYSE:EPAC) on 10/25/2024.
• Purchased $1,001 – $15,000 in shares of Disco (OTCMKTS:DSCSY) on 10/25/2024.

ICU Medical Stock Down 0.3 %

ICUI stock opened at $178.55 on Friday. The stock has a market cap of $4.36 billion, a PE ratio of -61.15 and a beta of 0.66. The firm’s 50-day simple moving average is $175.07 and its 200 day simple moving average is $139.41. ICU Medical, Inc. has a fifty-two week low of $78.28 and a fifty-two week high of $188.53. The company has a quick ratio of 1.08, a current ratio of 2.41 and a debt-to-equity ratio of 0.76.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Wednesday, August 7th. The medical instruments supplier reported $1.56 EPS for the quarter, beating the consensus estimate of $1.00 by $0.56. ICU Medical had a negative net margin of 3.07% and a positive return on equity of 5.01%. The company had revenue of $596.50 million for the quarter, compared to analyst estimates of $556.64 million. During the same quarter last year, the business earned $1.58 earnings per share. ICU Medical’s revenue was up 8.6% compared to the same quarter last year. As a group, sell-side analysts predict that ICU Medical, Inc. will post 3.81 EPS for the current year.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $156.04, for a total value of $1,872,480.00. Following the completion of the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at $16,320,691.72. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, CEO Vivek Jain sold 12,000 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $156.04, for a total transaction of $1,872,480.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at approximately $16,320,691.72. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the transaction, the vice president now owns 13,107 shares in the company, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 50,502 shares of company stock valued at $8,445,976 in the last three months. 6.70% of the stock is currently owned by company insiders.

Institutional Trading of ICU Medical

A number of large investors have recently added to or reduced their stakes in the business. Silvercrest Asset Management Group LLC raised its holdings in ICU Medical by 109.4% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 278,436 shares of the medical instruments supplier’s stock worth $29,882,000 after buying an additional 145,485 shares during the period. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of ICU Medical during the first quarter valued at approximately $15,425,000. Victory Capital Management Inc. lifted its position in shares of ICU Medical by 2,966.3% in the 2nd quarter. Victory Capital Management Inc. now owns 141,848 shares of the medical instruments supplier’s stock valued at $16,844,000 after acquiring an additional 137,222 shares in the last quarter. Millennium Management LLC boosted its stake in ICU Medical by 327.8% in the 2nd quarter. Millennium Management LLC now owns 136,070 shares of the medical instruments supplier’s stock worth $16,158,000 after purchasing an additional 104,264 shares during the period. Finally, Granite Investment Partners LLC purchased a new position in ICU Medical during the 2nd quarter worth approximately $10,650,000. 96.10% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ICUI has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a “hold” rating on shares of ICU Medical in a research note on Thursday, October 10th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Thursday, September 12th. Raymond James boosted their price target on shares of ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. KeyCorp increased their price objective on shares of ICU Medical from $147.00 to $198.00 and gave the company an “overweight” rating in a report on Tuesday, October 15th. Finally, Jefferies Financial Group began coverage on ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and an average price target of $170.25.

About Representative Gottheimer

Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2025. Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2024 election. Gottheimer was first elected to the House in 2016. Prior to his election, Gottheimer worked for Microsoft, the Federal Communications Commission, and for the administration of President Bill Clinton (D). Click here for more information about Gottheimer’s career. Gottheimer serves on the House Financial Services Committee, where is a member of three subcommittees. For more on Gottheimer’s committee assignments, click here. Gottheimer became a co-chair of the Problem Solvers Caucus in February 2017. Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.